Source: VentriPoint Diagnostics Ltd.
  • Ventripoint (VPT) will be exhibiting at the 70th European Society of Cardiology (ESC) Congress in Barcelona, Spain, from August 26 to 29
  • According to the Congress website reports, 40,000 participants from 170 countries will hear 5,000 medical presentations during the congress
  • This is another opportunity for Ventripoint to inform the cardiology community about its innovative VMS+ products
  • Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography
  • VentriPoint Diagnostics Ltd. (VPT) is down 1.59 per cent, trading at C$0.31 per share at 2:16 pm ET

Ventripoint (VPT) will be exhibiting at the 70th European Society of Cardiology (ESC) Congress in Barcelona, Spain, from August 26 to 29.

The spotlight in 2022 is “Cardiac imaging,” ever more critical in cardiovascular medicine with its profound implications from prevention to diagnosis, clinical decision-making, guiding interventions and therapeutic procedures.

According to the congress website, 40,000 participants from 170 countries will hear 5,000 medical presentations. The ESC will hold the conference virtually and in person for the first time. It will provide access to the latest cardiology research and clinical updates from anywhere in the world.

The ESC comprises clinicians, scientists, and other professionals in the cardiology field. The ESC aims to unite national cardiac societies worldwide to study further and understand cardiovascular disease.

This is another opportunity for Ventripoint to inform the cardiology community about its innovative VMS+ products. This follows the successful AEPC conference this past May in Geneva and the ASE conference in June in Seattle.

Ventripoint has become an industry leader in applying AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS+ products are powered by its proprietary KBR technology, resulting from a decade of development. It provides accurate volumetric cardiac measurements equivalent to MRI.

VentriPoint Diagnostics Ltd. (VPT) is down 1.59 per cent, trading at C$0.31 per share at 2:16 pm ET.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.